Table 2. Subjects characteristics at baseline after 6 weeks of antiviral treatment (n = 12).
| Variable (n = 12) | Baseline | 6-week treatment | p |
|---|---|---|---|
| BMI (kg/m2) | 23.0 ± 2.9 | 23.0 ± 2.9 | 0.999 |
| Body weight (Kg) | 67 ± 12.9 | 67.07 ± 13 | 0.815 |
| Waist circumference (cm) | 83.9 ± 13.3 | 78.2 ± 16.1 | 0.105 |
| Systolic BP (mmHg) | 121.4 ± 15.5 | 120.8 ± 13.9 | 0.881 |
| Diastolic BP (mmHg) | 76.6 ± 13.3 | 75.7 ± 11.5 | 0.775 |
| Glucose metabolism | |||
| Fasting glucose (mM) | 5.3 ± 0.5 | 5.3 ± 0.5 | 0.685 |
| Fasting insulin (μU/mL) | 12.0 ± 5.3 | 12.0 ± 4.0 | 0.977 |
| Liver enzymes | |||
| ASAT (U/L) | 54.9 ± 36.7 | 23.1 ± 2.4 | 0.013 |
| ALAT (U/L) | 87.5 ± 62.9 | 21.9 ± 4.6 | 0.003 |
| Alkaline phosphatase (U/L) | 59.9 ± 23.0 | 59.5 ± 20.0 | 0.879 |
| GGT (U/L) | 37.0 ± 21.6 | 17.6 ± 8.2 | 0.001 |
| Lipids | |||
| Cholesterol (mmol/L) | 4.2 ± 0.6 | 5.0 ± 1.1 | 0.001 |
| TG (mmol/L) | 1.4 ± 0.6 | 1.3 ± 0.7 | 0.776 |
| LDL (mmol/L) | 2.1 ± 0.6 | 2.8 ± 0.9 | 0.0006 |
| HDL (mmol/L) | 1.5 ± 0.37 | 1.6 ± 0.6 | 0.293 |
| Subcutaneos fat volume | 232.6 ± 118.5 | 228.7 ± 114.3 | 0.385 |
| Visceral fat volume | 84.3 ± 67.3 | 85.83 ± 70.4 | 0.447 |
| HCV RNA Log10 (IU/mL) | 6.4 ± 6.6 | <1.2 | - |
Abbreviations: BMI, body mass index; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; GGT, gamma glutamyl transpeptidase; TG, triglycerides; LDL, low-density cholesterol; HDL, high density cholesterol. Data are means ± SD.